Glaucoma Trials Tracker

Clinical Report: Glaucoma Trials Tracker

Background

Glaucoma is a leading cause of irreversible blindness worldwide. Recent updates to clinical guidelines emphasize the importance of evidence-based approaches in treatment selection and monitoring.

Data Highlights

Trial Name	Purpose	Enrollment	Status
Reformulated PG324 Ophthalmic Solution	Intraocular Pressure Reduction	Not specified	Completed
VisiPlate Aqueous Shunt	Evaluate safety and effectiveness	165	Active
Comparison of Goniotomy Devices	Effectiveness in combined surgeries	132	Active
Second Generation Travoprost Implant	Safety and efficacy evaluation	510	Active
Rocklatan vs Latanoprost	Evaluate treatment outcomes	36	Active
Direct vs Standard SLT	Noninferiority trial	172	Active

Key Findings

Reformulated PG324 is aimed at reducing intraocular pressure.
The VisiPlate Aqueous Shunt trial evaluates a new device for refractory open-angle glaucoma.
Comparison of goniotomy devices seeks to determine the most effective option during cataract surgery.
The second generation travoprost intracameral implant is being compared to timolol ophthalmic solution.
Rocklatan is being evaluated against latanoprost following Direct Selective Laser Trabeculoplasty.
Direct selective laser trabeculoplasty is being compared to standard selective laser trabeculoplasty in a noninferiority trial.

Clinical Implications

The ongoing trials provide insights into new therapeutic options for managing glaucoma, particularly for patients who have not responded to standard treatments. Understanding the outcomes of these trials will be important for clinicians in making informed treatment decisions.

Conclusion

Active interventional trials in glaucoma are crucial for advancing treatment strategies and improving patient care. Continued monitoring of these studies will enhance understanding of effective management approaches.